Form 4: Amicus Therapeutics Director Glenn Sblendorio Receives Significant Equity Awards

Amicus Therapeutics, Inc. Director Glenn Sblendorio was granted 20,414 Restricted Stock Units and options to purchase 74,872 shares of common stock, aligning his interests with long-term shareholder value.

Summary

• Glenn Sblendorio, a Director at Amicus Therapeutics, Inc. (FOLD), was granted equity awards on June 5, 2025.
• The awards include 20,414 Restricted Stock Units (RSUs), which will vest in full on the one-year anniversary of the grant date (June 5, 2026) and are payable in common stock.
• Additionally, Mr. Sblendorio received options to purchase 74,872 shares of common stock with an exercise price of $5.96 per share.
• These stock options will also vest 100% on the one-year anniversary of the grant date (June 5, 2026) and have an expiration date of June 5, 2035.
• Following these transactions, Mr. Sblendorio directly beneficially owns 115,857 shares of common stock and 74,872 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's a standard compensation practice, hence not a 'strong buy' signal on its own, but certainly not negative.

Positives

• The grant of Restricted Stock Units (RSUs) and stock options to Director Glenn Sblendorio aligns his interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• The acquisition of 20,414 RSUs and 74,872 stock options indicates continued commitment and confidence from a key board member in Amicus Therapeutics' future.
• The vesting schedule, one year from the grant date, provides an incentive for long-term performance and retention of the director.

Risks

• The value of the granted equity awards (RSUs and stock options) is subject to the future performance of Amicus Therapeutics' common stock, meaning the actual realized value could be lower than the current implied value if the stock price declines.
• The options have an exercise price of $5.96, meaning they will only be 'in the money' and valuable if the stock price exceeds this amount after vesting.

Future Outlook

The vesting schedules for the granted RSUs and stock options, set for the one-year anniversary of the grant date, imply a forward-looking incentive for the director to contribute to the company's performance over the next year.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of compensation to align management and board interests with long-term shareholder value creation. This grant to a director at Amicus Therapeutics is consistent with typical compensation structures in the sector.

Related Party Transactions

• The reported transactions are equity grants from Amicus Therapeutics, Inc. to Glenn Sblendorio, a director of the company. These are by definition related party transactions as they involve an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of shareholders, potentially incentivizing decisions that enhance long-term stock value.
• Employees: While not directly impacting general employees, such grants to leadership can signal stability and confidence, indirectly affecting morale.

Next Steps

• The 20,414 Restricted Stock Units (RSUs) are expected to vest in full on June 5, 2026.
• The 74,872 stock options are expected to vest and become exercisable on June 5, 2026.

Key Dates

Recommendation

Keywords

Amicus Therapeutics, FOLD, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Glenn Sblendorio, Beneficial Ownership